Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) LONDON & KENILWORTH, N.J.–(BUSINESS WIRE)–GSK and Merck, […]
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2015-11-03 06:58:452015-11-03 12:27:02GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
